
DNTOX GmbH is a German bioanalytical testing laboratory specializing in animal-free in vitro screening of chemicals to assess their potential to disrupt human brain development and cause developmental neurotoxicity (DNT). The company uses human neural progenitor cells and induced pluripotent stem cells cultivated in 2D and 3D cultures to study neurodevelopmental and neuronal processes. DNTOX offers services including developmental neurotoxicity testing, adult neurotoxicity testing using 3D BrainSpheres and multi-electrode arrays, and computational biology with AI-based microscopy image and video analysis software. Their business model is service-based, supporting chemical safety assessment and substance development with innovative, animal-free testing methods. DNTOX is recognized in the regulatory field with methods promoted by OECD, EFSA, and US EPA, and participates in international scientific advisory boards and events, positioning it as a leader in alternative neurotoxicity testing.

DNTOX GmbH is a German bioanalytical testing laboratory specializing in animal-free in vitro screening of chemicals to assess their potential to disrupt human brain development and cause developmental neurotoxicity (DNT). The company uses human neural progenitor cells and induced pluripotent stem cells cultivated in 2D and 3D cultures to study neurodevelopmental and neuronal processes. DNTOX offers services including developmental neurotoxicity testing, adult neurotoxicity testing using 3D BrainSpheres and multi-electrode arrays, and computational biology with AI-based microscopy image and video analysis software. Their business model is service-based, supporting chemical safety assessment and substance development with innovative, animal-free testing methods. DNTOX is recognized in the regulatory field with methods promoted by OECD, EFSA, and US EPA, and participates in international scientific advisory boards and events, positioning it as a leader in alternative neurotoxicity testing.
Founded: 2022
Headquarters: Düsseldorf, Germany
Focus: Human cell–based, animal-free in vitro developmental and adult neurotoxicity testing
Business model: Service-based bioanalytical testing and computational biology
Seed funding: Seed round announced Jun 14, 2023; reported €1.4M
Assessing chemical impacts on human brain development and neuronal function without animal testing.
2022
Biotechnology
€1.4M
Reported investor participation also includes Bool Capital, AQAL Integral Investing, Nikolaus Sturm, and Barbara Korte-Sturm.
“Led by a prominent German seed investor (HTGF) with participation from VC and angel investors”
| Company |
|---|